Top Midday Decliners

MT Newswires Live03-03

Aardvark Therapeutics (AARD) said late Friday it paused its phase 3 trial of ARD-101 for hyperphagia in patients with Prader-Willi Syndrome after reversible cardiac observations at above target therapeutic doses were found during routine safety monitoring in a healthy volunteer study.

RBC downgraded the stock to sector perform from outperform. Other downgrades include HC Wainwright to neutral from buy.

Shares sank 56% Monday, with intraday trading volume of over 2.24 million against a daily average of about 191,000.

uniQure (QURE) shares tumbled 32% after the US Food and Drug Administration said data from the company's phase 1/2 trials was not sufficient to provide the primary evidence of effectiveness needed to support a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.

More than 13.7 million shares traded intraday, compared with a daily average of about 2.64 million.

Price: 5.46, Change: -7.03, Percent Change: -56.29

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616536317?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 03:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616536317","market":"fut","top_or_hot":-1,"title":"Top Midday Decliners","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> (AARD) said late Friday it paused its phase 3 trial of ARD-101 for hyperphagia in patients with Prader-Willi Syndrome after reversible cardiac observations at above target therapeutic doses were found during routine safety monitoring in a healthy volunteer study.</p><p>RBC downgraded the stock to sector perform from outperform. Other downgrades include HC Wainwright to neutral from buy.</p><p>Shares sank 56% Monday, with intraday trading volume of over 2.24 million against a daily average of about 191,000.</p><p>uniQure (QURE) shares tumbled 32% after the US Food and Drug Administration said data from the company's phase 1/2 trials was not sufficient to provide the primary evidence of effectiveness needed to support a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.</p><p>More than 13.7 million shares traded intraday, compared with a daily average of about 2.64 million.</p><p>Price: 5.46, Change: -7.03, Percent Change: -56.29</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Decliners\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-03 03:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/AARD\">Aardvark Therapeutics</a> (AARD) said late Friday it paused its phase 3 trial of ARD-101 for hyperphagia in patients with Prader-Willi Syndrome after reversible cardiac observations at above target therapeutic doses were found during routine safety monitoring in a healthy volunteer study.</p><p>RBC downgraded the stock to sector perform from outperform. Other downgrades include HC Wainwright to neutral from buy.</p><p>Shares sank 56% Monday, with intraday trading volume of over 2.24 million against a daily average of about 191,000.</p><p>uniQure (QURE) shares tumbled 32% after the US Food and Drug Administration said data from the company's phase 1/2 trials was not sufficient to provide the primary evidence of effectiveness needed to support a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.</p><p>More than 13.7 million shares traded intraday, compared with a daily average of about 2.64 million.</p><p>Price: 5.46, Change: -7.03, Percent Change: -56.29</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AARD","symbol_name":"Aardvark Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616536317","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616536317","pubTimestamp":1772479865,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Aardvark Therapeutics  said late Friday it paused its phase 3 trial of ARD-101 for hyperphagia in patients with Prader-Willi Syndrome after reversible cardiac observations at above target therapeutic doses were found during routine safety monitoring in a healthy volunteer study.RBC downgraded the stock to sector perform from outperform. Other downgrades include HC Wainwright to neutral from buy.Shares sank 56% Monday, with intraday trading volume of over 2.24 million against a daily average of about 191,000.uniQure  shares tumbled 32% after the US Food and Drug Administration said data from the company's phase 1/2 trials was not sufficient to provide the primary evidence of effectiveness needed to support a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.More than 13.7 million shares traded intraday, compared with a daily average of about 2.64 million.Price: 5.46, Change: -7.03, Percent Change: -56.29","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AARD":"Aardvark Therapeutics","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","QURE":"uniQure N.V.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"午盘跌幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AARD":1,"QURE":1},"content_text":"Aardvark Therapeutics (AARD) said late Friday it paused its phase 3 trial of ARD-101 for hyperphagia in patients with Prader-Willi Syndrome after reversible cardiac observations at above target therapeutic doses were found during routine safety monitoring in a healthy volunteer study.RBC downgraded the stock to sector perform from outperform. Other downgrades include HC Wainwright to neutral from buy.Shares sank 56% Monday, with intraday trading volume of over 2.24 million against a daily average of about 191,000.uniQure (QURE) shares tumbled 32% after the US Food and Drug Administration said data from the company's phase 1/2 trials was not sufficient to provide the primary evidence of effectiveness needed to support a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.More than 13.7 million shares traded intraday, compared with a daily average of about 2.64 million.Price: 5.46, Change: -7.03, Percent Change: -56.29","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616536317","isCrawlerRequest":true}